Semaglutide is effectively tolerated without any risk of hypoglycaemia in monotherapy but suffers from gastrointestinal adverse outcomes. A big population influenced with COVID-19 an infection have been diabetic; thus use of semaglutide in diabetic issues as well as CV individuals could well be very much supportive in protecting health care https://johnc332nyi4.blog5star.com/profile